Dissolved and financials
CVR: 27919995
Previous names: K/S BI BIOMEDICAL VENTURE ANNEX II
DKK -133,000
Gross profit
Net result: DKK -914,000
No current owners
CVR · view owners
No current management
CVR · view management
Dissolved
Ceased 30 March 2021
CVR · view overview
No headcount reported
Director role ended: SUNSTONE LSV GENERAL PARTNER BI ApS
CVR · 30/03/2021
View the full event history
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II was a Danish company of the type Kommanditselskab based in København K, founded in 2004. The company has been dissolved on 30 March 2021. The company was registered under the industry Ventureselskaber og kapitalfonde. The company was previously named K/S BI BIOMEDICAL VENTURE ANNEX II. In 2019, the company reported a gross profit of DKK -133,000 and a net result of DKK -914,000 compared with DKK -2,578,000 the year before. Equity in the 2019 report amounted to DKK 2,305,000.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 201901/01/2019 – 31/12/2019 | -133K | -914K | 2.4M | 2.3M | - | |
| 201801/01/2018 – 31/12/2018 | -250K | -2.6M | 4.2M | 4.2M | - | |
| 201701/01/2017 – 31/12/2017 | -49K | -301K | 8.8M | 8.8M | - | |
| 201601/01/2016 – 31/12/2016 | -6.5M | -21.5M | 9.3M | 9.3M | - | |
| 201501/01/2015 – 31/12/2015 | -35K | 49.5M | 112.4M | 112.4M | - | |
| 201401/01/2014 – 31/12/2014 | -43K | 16.2M | 69.3M | 69.2M | - | |
| 201301/01/2013 – 31/12/2013 | -57K | -15.9M | 62.1M | 62.1M | - | |
| 201201/01/2012 – 31/12/2012 | -109K | 23.3M | 85.3M | 85.2M | - |
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorNo. K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II is registered in the Danish CVR register with the status Dissolved and ceased on 30 March 2021.
The CVR number of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II is 27919995.
In 2019, K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II reported a gross profit of DKK -133,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II was founded on 18 June 2004.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II was registered under the industry Ventureselskaber og kapitalfonde (industry code 643040).
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II was located at Store Strandstræde 18A st., 1255 København K.
As of March 30, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of March 30, 2021, SUNSTONE LSV GENERAL PARTNER BI ApS has stepped down as director of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II was dissolved on March 30, 2021.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2019. Gross profit came to DKK -133,000, and the net result was DKK -914,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2018. Gross profit came to DKK -250,000, and the net result was DKK -2,578,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2017. Gross profit came to DKK -49,000, and the net result was DKK -301,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2016. Gross profit came to DKK -6,546,000, and the net result was DKK -21,544,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2015. Gross profit came to DKK -35,000, and the net result was DKK 49,453,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2014. Gross profit came to DKK -43,000, and the net result was DKK 16,232,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2013. Gross profit came to DKK -57,000, and the net result was DKK -15,936,000.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II has published its annual report for 2012. Gross profit came to DKK -109,000, and the net result was DKK 23,310,000.
As of November 17, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of November 17, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 9, 2010, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 9, 2010, EY Godkendt Revisionspartnerselskab has stepped down as auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of December 17, 2009, Lars Christian Bruhn has left the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of December 17, 2009, Bent Pedersen has left the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of December 17, 2009, SUNSTONE LSV GENERAL PARTNER BI ApS is registered as director of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of December 17, 2009, Thomas Tscherning has stepped down as daglig ledelse of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of December 17, 2009, Børge Obel has stepped down as vice chairman of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of December 17, 2009, Uffe Ellemann-Jensen has stepped down as chairman of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
On December 17, 2009, the company changed its name from K/S BI BIOMEDICAL VENTURE ANNEX II to K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of January 7, 2009, Thomas Tscherning is registered as daglig ledelse of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of January 7, 2009, Jesper Zeuthen has stepped down as daglig ledelse of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of September 8, 2008, Lars Kolind has left the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 28, 2008, EY Godkendt Revisionspartnerselskab has been appointed auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 28, 2008, CJ Partnership I/S has stepped down as auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 30, 2007, Lars Christian Bruhn has joined the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 30, 2007, Asger Ib Mardahl-Hansen has left the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of April 25, 2005, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, CJ Partnership I/S has been appointed auditor of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, Lars Kolind has joined the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, Asger Ib Mardahl-Hansen has joined the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, Bent Pedersen has joined the board of directors of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, Børge Obel is registered as vice chairman of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, Uffe Ellemann-Jensen is registered as chairman of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
As of June 18, 2004, Jesper Zeuthen is registered as daglig ledelse of K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II.
K/S SUNSTONE BIOMEDICAL VENTURE ANNEX II was founded on June 18, 2004.

Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.

Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.

Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.


Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed